Rainmed Medical Limited (HK:2297)
:2297
Top Page
Rainmed Medical Limited
(2297)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$0.50
▲(92.31% Upside)
Action:ReiteratedDate:10/31/25
Rainmed Medical Limited's overall stock score of 43 reflects significant challenges, primarily driven by weak financial performance with severe profitability issues and negative cash flows, despite a stable balance sheet. Technical analysis further weighs on the score with bearish price trends and momentum indicators. Valuation remains neutral due to the lack of positive earnings and dividend data. Investors should approach with caution given the operational and revenue decline risks.
Positive Factors
Strong Equity Position
A strong equity position indicates financial stability and low financial risk, providing a solid foundation for potential future growth and investment.
Negative Factors
Declining Revenues
Declining revenues indicate challenges in market demand or competitive positioning, which can impact long-term profitability and growth potential.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Equity Position
A strong equity position indicates financial stability and low financial risk, providing a solid foundation for potential future growth and investment.
Read all positive factors
Rainmed Medical Limited (2297) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$385.37M
Dividend YieldN/A
Average Volume (3M)3.71M
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue Growth-53.10%
EPS Growth5.79%
CountryHK
Employees270
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,401,358,800
10 Day Avg. Volume1,490,900
30 Day Avg. Volume3,709,666
Financial Highlights & Ratios
PEG Ratio-1.99
Price to Book (P/B)0.45
Price to Sales (P/S)4.58
P/FCF Ratio-1.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rainmed Medical Limited Business Overview & Revenue Model
Company Description
Rainmed Medical Limited, a medical device company, focus on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microvascular resistance systems. ...
How the Company Makes Money
Rainmed Medical Limited generates revenue primarily through the sale of its medical devices and diagnostic solutions. Its revenue model is centered around direct sales to healthcare institutions, which includes hospitals and clinics, as well as pa...
Rainmed Medical Limited Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
75
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.36M | 39.82M | 73.22M | 83.60M | 81.20M | 6.10M |
| Gross Profit | 10.33M | 23.87M | 48.55M | 69.82M | 69.03M | 5.26M |
| EBITDA | -62.34M | -82.98M | -93.54M | -1.33B | -623.97M | -148.23M |
| Net Income | -104.02M | -113.50M | -115.83M | -1.35B | -633.64M | -145.24M |
Balance Sheet | ||||||
| Total Assets | 504.25M | 463.06M | 573.31M | 690.33M | 640.19M | 70.52M |
| Cash, Cash Equivalents and Short-Term Investments | 200.75M | 205.55M | 335.28M | 578.96M | 559.14M | 30.59M |
| Total Debt | 33.80M | 25.58M | 20.00M | 28.98M | 1.38B | 23.55M |
| Total Liabilities | 96.95M | 53.15M | 53.30M | 71.69M | 1.41B | 291.46M |
| Stockholders Equity | 405.50M | 407.00M | 515.05M | 618.64M | -774.48M | -220.93M |
Cash Flow | ||||||
| Free Cash Flow | -80.60M | -138.10M | -235.27M | -141.04M | -103.95M | -1.76M |
| Operating Cash Flow | -43.11M | -84.31M | -124.29M | -111.22M | -72.83M | 2.27M |
| Investing Cash Flow | -13.77M | 6.31M | 180.29M | -515.74M | -27.98M | 8.69M |
| Financing Cash Flow | 0.00 | 723.00K | -15.88M | 120.73M | 633.85M | 9.53M |
Rainmed Medical Limited Technical Analysis
Positive
0.26
Price Trends
0.28
Positive
0.28
Positive
0.29
Negative
Market Momentum
>-0.01
Positive
48.71
Neutral
51.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2297, the sentiment is Positive. The current price of 0.26 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.28, and below the 200-day MA of 0.29, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.71 is Neutral, neither overbought nor oversold. The STOCH value of 51.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2297.
Rainmed Medical Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$1.87B | 22.44 | 3.90% | ― | 32.93% | ― | |
58 Neutral | HK$8.16B | 27.86 | 4.88% | 0.48% | 35.01% | 483.73% | |
53 Neutral | HK$965.82M | -1.91 | -30.05% | ― | -8.56% | -14.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$385.37M | -1.99 | -25.60% | ― | -53.10% | 5.79% | |
43 Neutral | HK$3.69B | -218.71 | 0.22% | ― | -4.38% | ― | |
41 Neutral | HK$724.37M | -4.03 | -9.19% | ― | -30.60% | 28.61% |
* Healthcare Sector Average
HK:2297
Rainmed Medical Limited
0.28
0.10
58.05%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
23.70
7.31
44.64%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.90
-1.65
-36.26%
HK:2216
Broncus Holding Corp.
1.37
0.54
65.06%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.19
0.38
20.99%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
48.16
21.46
80.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.